Welcome to the e-CCO Library!

DOP50 The landscape of somatic mutations in non-neoplastic IBD-affected colon
Year: 2020
Source:

ECCO'20 Vienna

Authors:

S. Olafsson1, R.E. McIntyre1, T. Coorens2, T. Butler2, P. Robinson2, H. Lee-Six2, M. Sanders2, K. Arestang3, C. Dawson3, M. Tripathi4, K. Strongili3, Y. Hooks2, M.R. Stratton2, M. Parkes3, I. Martincorena2, T. Raine3, P.J. Campbell2, C.A. Anderson1

Created: Thursday, 30 January 2020, 10:12 AM
DOP50: Effect of upadacitinib on extra-intestinal manifestations in patients with moderate to severe Crohn’s disease: data from the CELEST study
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

L. Peyrin-Biroulet*1, S. Danese2, E. Louis3, P. D. R. Higgins4, M. Dubinsky5, F. Cataldi6, Q. Zhou6, W-J. Lee6, K. Kligys6, A. P. Lacerda6

Created: Friday, 22 February 2019, 9:41 AM
DOP50: Impact of Inflammatory Bowel Disease associated dysbiosis on bacterial quorum sensing mediated by Acyl-homoserine Lactone in human gut microbiota
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Grellier, N.(1,2,3)*;Suzuki, M.(4);Brot, L.(1);Rodrigues, A.(4);Humbert, L.(1);Escoubeyrou, K.(4);Rainteau, D.(1);Grill, J.P.(1);Lami, R.(4);Seksik, P.(1,3);
Created: Friday, 14 July 2023, 10:43 AM
DOP50: Oral α4β7 integrin inhibitor MORF-057 demonstrates exposure driven biomarker response in non-human primates
Year: 2022
Source: ECCO'22
Authors: Wong, J.(1);Lee, D.(2);Mangada, M.(3);Yadav, V.(3);Troast, D.(4);Zhong, C.(4);Hahn, K.(4);Wang, W.(5);Ge, X.(5);Sun, L.(5);Jiang, S.(5);Wang, B.(5);Zhang, J.(5);Yan, L.(5);Nguyen, H.(6);Cui, D.(2);Bursavich, M.G.(4);Lippa, B.(4);Rogers, B.N.(7);Ray, A.S.(8);
Created: Friday, 11 February 2022, 3:52 PM
DOP50: PINPOINT: The epidemiology of paediatric-onset Inflammatory Bowel Disease in the United Kingdom – a prospective, national, cohort study.
Year: 2024
Source: ECCO'24 Stockholm
Authors: Henderson, Paul
Created: Tuesday, 30 April 2024, 5:03 PM
DOP50: Recommencement of Inflammatory Bowel Disease medications following colectomy for Ulcerative Colitis
Year: 2021
Source: ECCO'21 Virtual
Authors: Ledder, O.(1);Lujan, R.(1);Orlanski-Meyer, E.(1);Friss, C.(1);Loewenberg Weisband, Y.(2);Greenfeld, S.(3);Kariv, R.(3);Lederman, N.(4);Matz, E.(5);Focht, G.(1);Yanai, H.(6);Ollech, Y.(6);Dotan, I.(6);Turner, D.(1)
Created: Wednesday, 2 June 2021, 4:12 PM
DOP50: The landscape of somatic mutations in non-neoplastic IBD-affected colon
Year: 2020
Source: ECCO'20 Vienna
Authors: Carl Anderson
Created: Tuesday, 23 June 2020, 5:40 PM
DOP50: The landscape of somatic mutations in non-neoplastic IBD-affected colon
Year: 2020
Source: ECCO'20 Vienna
Authors: Carl Anderson
Created: Tuesday, 23 June 2020, 4:58 PM
Files: 1
DOP51 Investigation on the role of Par4-associated cell polarity and associated barrier defects in inflammatory bowel diseases
Year: 2020
Source:

ECCO'20 Vienna

Authors:

F. Branchi, C. Heldt, B. Siegmund, M. Schumann

Created: Thursday, 30 January 2020, 10:12 AM
DOP51: Biomarker and pharmacokinetic data from the TURANDOT II open-label extension study of the anti-mucosal addressin cell adhesion molecule-1 (MAdCAM-1) antibody SHP647 in patients with ulcerative colitis
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

W. Reinisch*1, W. J. Sandborn2, S. Danese3, X. Hébuterne4, M. Kłopocka5, D. Tarabar6, T. Vaňásek7, M. Greguš8, P. A. Hellstern9, J. S. Kim10, M. Sparrow11, K. J. Gorelick12, M. Goetsch13, C. Bliss14, C. Gupta15, F. Cataldi14, S. Vermeire16

Created: Friday, 22 February 2019, 9:41 AM
DOP51: Biomarker and pharmacokinetic data from the TURANDOT II open-label extension study of the anti-mucosal addressin cell adhesion molecule-1 (MAdCAM-1) antibody SHP647 in patients with ulcerative colitis
Year: 2019
Source: ECCO'19 Copenhagen
Authors: Walter Reinisch
Created: Tuesday, 28 May 2019, 3:32 PM
Ulcerative colitis, Calprotectin and other faecal biomarkers, CRP and other serum biomarkers
Files: 1
DOP51: De-escalation of biological therapy in Inflammatory Bowel Disease patients following prior escalation
Year: 2021
Source: ECCO'21 Virtual
Authors: Thomas, P.(1);Smits, L.(1);Te Groen, M.(1);West, R.(2);Russel, M.(3);Jansen, J.(4);Römkens, T.(5);Hoentjen, F.(1)
Created: Wednesday, 2 June 2021, 4:12 PM
DOP51: Investigation on the role of Par4-associated cell polarity and associated barrier defects in Inflammatory Bowel Diseases
Year: 2020
Source: ECCO'20 Vienna
Authors: Federica Branchi
Created: Tuesday, 23 June 2020, 5:40 PM
DOP51: Investigation on the role of Par4-associated cell polarity and associated barrier defects in Inflammatory Bowel Diseases
Year: 2020
Source: ECCO'20 Vienna
Authors: Federica Branchi
Created: Tuesday, 23 June 2020, 4:58 PM
Files: 1
DOP51: Loss of PTPN23 in the intestinal epithelium results in epithelial hyperproliferation and lethal diarrhea in a microbiota dependent manner
Year: 2022
Source: ECCO'22
Authors: Spalinger, M.(1);Sanchez Alvarez, R.(1);Gottier, C.(1);Montalban-Arques, A.(1);Schwarzfischer, M.(1);Niechcial, A.(1);Scharl, M.(1);
Created: Friday, 11 February 2022, 3:52 PM
DOP51: Mucosa-associated microbial signatures associate with objective response prior to the start of anti-TNFα but not vedolizumab or ustekinumab in Crohn's disease patients
Year: 2023
Source: ECCO’23 Copenhagen
Authors: HagemanMD, I.(1)*;Joustra, V.(2);Zafeiropoulou , K.(1);Davids, M.(3);Hakvoort, T.(1);Probert, F.(4);Satsangi, J.(5);D'Haens, G.(2);De Jonge, W.(1);
Created: Friday, 14 July 2023, 10:43 AM
DOP51: Risk of kidney failure in patients with Inflammatory Bowel Disease undergoing colectomy: a nationwide cohort study
Year: 2024
Source: ECCO'24 Stockholm
Authors: Yang, Yuanhang
Created: Tuesday, 30 April 2024, 5:03 PM
DOP52 The phenotype of NOD-scid IL-2Rγnull mice reconstituted with peripheral blood mononuclear cells from patients with Crohn’s disease or ulcerative colitis reflects the respective disease
Year: 2020
Source:

ECCO'20 Vienna

Authors:

A. Unterweger1, J. Caesar1, P. Winkelmann1, A. Rüscher1, M. Seuß1, S. Breiteneicher5, J. Stallhofer5, F. Beigel5, M. Siebeck1, R. Gropp1

Created: Thursday, 30 January 2020, 10:12 AM